Abstract
Chemo- and radiotherapies that target DNA are the mainstay of cancer treatment. In response to DNA damage, cells are arrested in multiple checkpoints in the cell cycle to allow the damaged DNA to be repaired before progressing into mitosis. Normal cells are arrested in the G1 phase mediated by the p53 tumor suppressor, and p53-deficient cancer cells are arrested in the S or G2 phase. Checkpoint kinase 1 (Chk 1) is a serine / threonine protein kinase and a key mediator in the DNA damage-induced checkpoint network. When the G2 or S checkpoint is abrogated by the inhibition of Chk1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, Chk1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient. This review discusses the rationale of Chk1 as an anticancer target, the structural basis for designing Chk1 inhibitors, and recently disclosed Chk1 inhibitors.
Keywords: Chk1 inhibitor, Anticancer agent, DNA-damaging agent, Adjuvant therapy, DNA damage, Cell cycle, checkpoint, Kinase, Singnal transduction
Anti-Cancer Agents in Medicinal Chemistry
Title: Chk1 Inhibitors for Novel Cancer Treatment
Volume: 6 Issue: 4
Author(s): Zhi-Fu Tao and Nan-Horng Lin
Affiliation:
Keywords: Chk1 inhibitor, Anticancer agent, DNA-damaging agent, Adjuvant therapy, DNA damage, Cell cycle, checkpoint, Kinase, Singnal transduction
Abstract: Chemo- and radiotherapies that target DNA are the mainstay of cancer treatment. In response to DNA damage, cells are arrested in multiple checkpoints in the cell cycle to allow the damaged DNA to be repaired before progressing into mitosis. Normal cells are arrested in the G1 phase mediated by the p53 tumor suppressor, and p53-deficient cancer cells are arrested in the S or G2 phase. Checkpoint kinase 1 (Chk 1) is a serine / threonine protein kinase and a key mediator in the DNA damage-induced checkpoint network. When the G2 or S checkpoint is abrogated by the inhibition of Chk1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, Chk1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient. This review discusses the rationale of Chk1 as an anticancer target, the structural basis for designing Chk1 inhibitors, and recently disclosed Chk1 inhibitors.
Export Options
About this article
Cite this article as:
Tao Zhi-Fu and Lin Nan-Horng, Chk1 Inhibitors for Novel Cancer Treatment, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/187152006777698132
DOI https://dx.doi.org/10.2174/187152006777698132 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization
Current Medical Imaging Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders
Current Molecular Pharmacology Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Strategies for Targeting Lentiviral Vectors
Current Gene Therapy Microwave Assisted One-pot Three Component Synthesis of Novel 2-(5- Aryloxymethyl-1,3,4-thiadiazolo)-3-aryl-4-thiazolidinones
Letters in Organic Chemistry Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Drug Discovery by Targeting Mutant KRAS
Current Topics in Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets Editorial
Reviews on Recent Clinical Trials “Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma
Current Cancer Drug Targets Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences Adolescent Girls and their Mothers’ Knowledge and Opinions about Human Papilloma Virus Vaccine
Current Women`s Health Reviews Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy A Review on Targeting Nanoparticles for Breast Cancer
Current Pharmaceutical Biotechnology